Prospective single blind, single period, single treatment, single centered, Phase II study of polyherbal hepatoprotective traditional formulation - RVSPHF567 in the management of KAAMALA with special reference to Hepatitis

Pharmacognostical studies on selected popular hepatoprotective traditional herbal formulation

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2012/05/002701

Enrollment

Registered

2012-05-28

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Hepatitis

Interventions

Intervention1: RVSPHF567 contains Ajowan, Cardamom, Clove, Cumin, Mace, Nutmeg: 3.33gms TID PO Total Duration of Therapy: 3 days, Follow-up on 05th, 14th and 21st days. Control Intervention1: NA: NA C

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients from either sex 2. Patients between the Age group 18 - 30 years 3. Patients having signs and symptoms of hepatitis for a period of one month

Exclusion criteria

Exclusion criteria: 1. Patient suffering from any congenital hepatic failure and abnormalities 2. Patient suffering from obstructive jaundice or any carcinoma changes of liver 3. Patient suffering from any other systemic disorders 4. Patients at gestational or lactational period 5. Patient below and above the age group

Design outcomes

Primary

Measure	Time frame
1. To introduce a safe and effective polyherbal hepatoprotective formulation to the societyTimepoint: 30 days	—

Secondary

Measure	Time frame
1. To introduce a economical treatment for the societyTimepoint: 45 days	—

Countries

India

Contacts

Public ContactCS KANDASAMY

College of Pharmacy

gopalveni@yahoo.com09894832221

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026